questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NHS England’s decision not to commission abiraterone acetate plus prednisone/prednisolone for men with high risk non metastatic prostate cance
answerText: NHS England develops an Equality and Health Inequalities Impact Assessment (EHIA) for policy propositions included in its Policy Work Programme. The EHIA for abiraterone acetate plus prednisone for hormone sensitive non-metastatic prostate cancer noted th...
heading: Prostate Cancer: Hormone Treatments